BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: De Mattia E, Cecchin E, Guardascione M, Foltran L, Di Raimo T, Angelini F, D’Andrea M, Toffoli G. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol 2019; 25(29): 3870-3896 [PMID: 31413525 DOI: 10.3748/wjg.v25.i29.3870]
URL: https://www.wjgnet.com/1007-9327/full/v25/i29/3870.htm
Number Citing Articles
1
Zu‐Yau Lin, Ming‐Lun Yeh, Ching‐I Huang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang. Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expressionThe Kaohsiung Journal of Medical Sciences 2022; 38(2): 157 doi: 10.1002/kjm2.12471
2
QingTao Ni, Chi Pan, ShengBin Dai, Peng Wang. <p>Immunotherapy Combined with Chemotherapy as a Promising Therapy for a EGFR Exon 19 Deletion with MET Amplification Patient with Non-Small-Cell Lung Cancer: A Case Report</p>OncoTargets and Therapy 2020; : 3039 doi: 10.2147/OTT.S243988
3
Yinghai Xie, Changwei Liu, Shuping Zhou, Qi Wang, Xiaolong Tang. Lupeol-Loaded Nanoparticles Enhance the Radiosensitivity of Hepatocellular Carcinoma by Inhibiting the Hyperactivation in Raf/Mitogen-Activated Protein Kinase and Phospatidylinositol-3 Kinase/mTOR PathwaysJournal of Biomedical Nanotechnology 2021; 17(11): 2247 doi: 10.1166/jbn.2021.3194
4
Ying Zhao, Guo-Sheng He, Gong Li. Triplet regimen as a novel modality for advanced unresectable hepatocellular carcinoma: A case report and review of literatureWorld Journal of Clinical Cases 2023; 11(27): 6558-6564 doi: 10.12998/wjcc.v11.i27.6558
5
Mohammad K. Mohammad, Guoli Chen. Practical Oncologic Molecular Pathology2021; : 171 doi: 10.1007/978-3-030-73227-1_8
6
Zengbin Wang, Linqing Wu, Yu Zhou, Zhong Chen, Tao Zhang, Hong Wei, Zhihong Wang. Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cellsFrontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1394241
7
Giovanni Galati, Antonio Fabio Massimo Vainieri, Claudia Angela Maria Fulgenzi, Stefano Di Donato, Marianna Silletta, Paolo Gallo, Angelo Onorato, Umberto Vespasiani-Gentilucci, Antonio Picardi. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver CirrhosisCurrent Drug Metabolism 2020; 21(11): 866 doi: 10.2174/1389200221999200918141239
8
A. Yu. Goryainova, A. I. Stukan, R. A. Murashko, S. V. Sharov, O. I. Kirsanova, E. V. Lymar. Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitorsMeditsinskiy sovet = Medical Council 2021; (20): 84 doi: 10.21518/2079-701X-2021-20-84-93
9
Zu-Yau Lin, Ming-Lun Yeh, Ching-I. Huang, Po-Cheng Liang, Po-Yao Hsu, Shinn-Cherng Chen, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang. Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinomaBiomedicine & Pharmacotherapy 2022; 153: 113540 doi: 10.1016/j.biopha.2022.113540
10
Reyihanguli Aimaier, Haoran Li, Wenzhi Cao, Xiyuan Cao, Hui Zhang, Jia You, Jingjing Zhao, Qi Zhang, Li Yin, Qinshuang Mei, Xiaorong Zhang, Weiquan Wang, Huixin Zhao, Jinyu Li, Heping Zhao. The Secondary Metabolites of Bacillus subtilis Strain Z15 Induce Apoptosis in Hepatocellular Carcinoma CellsProbiotics and Antimicrobial Proteins 2023;  doi: 10.1007/s12602-023-10181-4
11
William A. Zammarrelli, Weining Ma, Kevin Espino, Sushmita Gordhandas, Effi Yeoshoua, Sarah Ehmann, Qin Zhou, Alexia Iasonos, Nadeem R. Abu-Rustum, Carol Aghajanian, Angela K. Green, Maria M. Rubinstein, Vicky Makker. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancerGynecologic Oncology 2023; 178: 27 doi: 10.1016/j.ygyno.2023.09.010
12
Dragica Pavlovic, Danijela Niciforovic, Dragana Papic, Katarina Milojevic, Marina Markovic. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative reviewTherapeutic Advances in Medical Oncology 2023; 15 doi: 10.1177/17588359231205848
13
Qinglong Yang, Gang Wu. CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expressionGastroenterología y Hepatología (English Edition) 2022; 45(10): 742 doi: 10.1016/j.gastre.2021.11.004
14
Stefano Fogli, Giulia Gianfilippo, Federico Cucchiara, Marzia Del Re, Laura Valerio, Rossella Elisei, Romano Danesi. Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancerCritical Reviews in Oncology/Hematology 2021; 163: 103366 doi: 10.1016/j.critrevonc.2021.103366
15
Zhengbin Zhao, Jing Gao, Shuangsheng Huang. LncRNA SNHG7 Promotes the HCC Progression Through miR-122-5p/FOXK2 AxisDigestive Diseases and Sciences 2022; 67(3): 925 doi: 10.1007/s10620-021-06918-2
16
Vahid Mansouri, Nima Beheshtizadeh, Maliheh Gharibshahian, Leila Sabouri, Mohammad Varzandeh, Nima Rezaei. Recent advances in regenerative medicine strategies for cancer treatmentBiomedicine & Pharmacotherapy 2021; 141: 111875 doi: 10.1016/j.biopha.2021.111875
17
Miaomiao Li, Juntao Hu, Riming Jin, Hongxia Cheng, Huaping Chen, Limin Li, Kun Guo. <p>Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma</p>Journal of Hepatocellular Carcinoma 2020; : 361 doi: 10.2147/JHC.S279123
18
Wei Zhang, Hui-Fang Kong, Xu-Dong Gao, Zheng Dong, Ying Lu, Jia-Gan Huang, Hong Li, Yong-Ping Yang. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinomaWorld Journal of Gastroenterology 2020; 26(35): 5287-5301 doi: 10.3748/wjg.v26.i35.5287
19
Jianrong Zheng, Liao Zeng, Mingqing Tang, Hongjun Lin, Chao Pi, Ruian Xu, Xiuling Cui. Novel Ferrocene Derivatives Induce G0/G1 Cell Cycle Arrest and Apoptosis through the Mitochondrial Pathway in Human Hepatocellular CarcinomaInternational Journal of Molecular Sciences 2021; 22(6): 3097 doi: 10.3390/ijms22063097
20
Yiran Chen, Li Li, Jie Lan, Yang Cui, Xiaosong Rao, Jing Zhao, Tao Xing, Gaoda Ju, Guangtao Song, Jizhong Lou, Jun Liang. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinomaMolecular Cancer 2022; 21(1) doi: 10.1186/s12943-021-01466-9
21
Hiroyuki Ogawa, Kosuke Kaji, Norihisa Nishimura, Hirotetsu Takagi, Koji Ishida, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosisJournal of Cellular and Molecular Medicine 2021; 25(8): 4001 doi: 10.1111/jcmm.16363
22
Wentao Bo, Yan Chen. Lenvatinib resistance mechanism and potential ways to conquerFrontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1153991
23
Yangjin Huang, Jun Xu, Chunming Xie, Yuejuan Liao, Rong Lin, Yuan Zeng, Fujun Yu. A Novel Gene Pair CSTF2/DPE2A Impacts Prognosis and Cell Cycle of Hepatocellular CarcinomaJournal of Hepatocellular Carcinoma 2023; : 1639 doi: 10.2147/JHC.S413935
24
Mengfei Han, Geliang Yang, Qing Lin, Yanlong Yang, Huiqing Zhang, Yonghua Su. Determination of Endogenous Bufalin in Serum of Patients With Hepatocellular Carcinoma Based on HPLC-MS/MSFrontiers in Oncology 2020; 9 doi: 10.3389/fonc.2019.01572
25
Gabriele Perrone, Luigi Rigacci, Giandomenico Roviello, Ida Landini, Alberto Fabbri, Lorenzo Iovino, Benedetta Puccini, Emanuele Cencini, Enrico Orciuolo, Monica Bocchia, Alberto Bosi, Enrico Mini, Stefania Nobili. Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patientsCancer Drug Resistance 2024;  doi: 10.20517/cdr.2024.10
26
Junjie Ao, Tetsuhiro Chiba, Shuhei Shibata, Akane Kurosugi, Na Qiang, Yaojia Ma, Motoyasu Kan, Terunao Iwanaga, Takafumi Sakuma, Hiroaki Kanzaki, Kengo Kanayama, Ryuta Kojima, Yuko Kusakabe, Masato Nakamura, Tomoko Saito, Ryo Nakagawa, Takayuki Kondo, Sadahisa Ogasawara, Eiichiro Suzuki, Ryosuke Muroyama, Jun Kato, Naoya Mimura, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cellsBiochemical and Biophysical Research Communications 2021; 549: 171 doi: 10.1016/j.bbrc.2021.02.097
27
Zu‐Yau Lin, Ming‐Lun Yeh, Ching‐I Huang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang. Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinomaThe Kaohsiung Journal of Medical Sciences 2021; 37(7): 616 doi: 10.1002/kjm2.12374
28
Li Du, Yichun Ji, Bing Xin, Jiemeng Zhang, Li-Chun Lu, Christopher K. Glass, Gen-Sheng Feng. Shp2 Deficiency in Kupffer Cells and Hepatocytes Aggravates Hepatocarcinogenesis by Recruiting Non-Kupffer MacrophagesCellular and Molecular Gastroenterology and Hepatology 2023; 15(6): 1351 doi: 10.1016/j.jcmgh.2023.02.011
29
Ran You, Yanjun Yang, Guowen Yin, Hao Jiang, Yousheng Lu, Liang Gui, Jun Bao, Qingyu Xu, Liang Feng. CPEB2 Suppresses Hepatocellular Carcinoma Epithelial–Mesenchymal Transition and Metastasis through Regulating the HIF-1α/miR-210-3p/CPEB2 AxisPharmaceutics 2023; 15(7): 1887 doi: 10.3390/pharmaceutics15071887
30
Guangzhen Ma, Jirong Chen, Tiantian Wei, Jia Wang, Wenshan Chen. Inhibiting roles of FOXA2 in liver cancer cell migration and invasion by transcriptionally suppressing microRNA-103a-3p and activating the GREM2/LATS2/YAP axisCytotechnology 2021; 73(4): 523 doi: 10.1007/s10616-021-00475-2
31
Huili Lai, Liping Zhong, Yong Huang, Yongxiang Zhao, Zhiyong Qian. Progress in Application of Nanotechnology in SorafenibJournal of Biomedical Nanotechnology 2021; 17(4): 529 doi: 10.1166/jbn.2021.3061
32
Luca Bedon, Michele Dal Bo, Monica Mossenta, Davide Busato, Giuseppe Toffoli, Maurizio Polano. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma PatientsInternational Journal of Molecular Sciences 2021; 22(3): 1075 doi: 10.3390/ijms22031075
33
Nurbubu T. Moldogazieva, Sergey P. Zavadskiy, Susanna S. Sologova, Innokenty M. Mokhosoev, Alexander A. Terentiev. Predictive biomarkers for systemic therapy of hepatocellular carcinomaExpert Review of Molecular Diagnostics 2021; 21(11): 1147 doi: 10.1080/14737159.2021.1987217
34
Gül KOCA, Sakou SEYDOU, Özlem YILDIRIM. Kanser immünoterapisinde güncel yaklaşımlar ve immünoterapinin sınırlayıcı etkilerine genel bakışTurkish Journal of Clinics and Laboratory 2022; 13(1): 153 doi: 10.18663/tjcl.1038881
35
Sara Armani, Andreas Geier, Thomas Forst, Uta Merle, David H. Alpers, Martin W. Lunnon. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactionsBritish Journal of Clinical Pharmacology 2024; 90(4): 942 doi: 10.1111/bcp.15990
36
Gloria Ravegnini, Giorgia Valori, Qianqian Zhang, Riccardo Ricci, Patrizia Hrelia, Sabrina Angelini. Pharmacogenetics in the treatment of gastrointestinal stromal tumors – an updated reviewExpert Opinion on Drug Metabolism & Toxicology 2020; 16(9): 797 doi: 10.1080/17425255.2020.1789589
37
Yiyin Chen, Banglun Pan, Jiacheng Qiu, Zhanfei Chen, Xiaoqian Wang, Nanhong Tang. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPKToxicology in Vitro 2021; 76: 105226 doi: 10.1016/j.tiv.2021.105226
38
Miao Li, Tingting Tan, Yu Geng, Yue Tao, Jie Pan, Jun Zhang, Qin Xu, Han Shen, Lingyun Zuo, Yuxin Chen. HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathwayAnnals of Hepatology 2023; 28(1): 100759 doi: 10.1016/j.aohep.2022.100759
39
Silvia Mezzalira, Elena De Mattia, Michela Guardascione, Chiara Dalle Fratte, Erika Cecchin, Giuseppe Toffoli. Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients’ Management and Therapy OutcomesInternational Journal of Molecular Sciences 2019; 20(21): 5498 doi: 10.3390/ijms20215498
40
Julia C. F. Quintanilha, Kelli Hammond, Yingmiao Liu, Federica Marmorino, Beatrice Borelli, Chiara Cremolini, Andrew B. Nixon, Federico Innocenti. Plasma levels of VEGF‐A and VCAM‐1 as predictors of drug‐induced hypertension in patients treated with VEGF pathway inhibitorsBritish Journal of Clinical Pharmacology 2022; 88(9): 4171 doi: 10.1111/bcp.15356
41
Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D’Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni, Massimo Negrini. miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer modelsMolecular Therapy - Nucleic Acids 2022; 29: 538 doi: 10.1016/j.omtn.2022.07.015
42
Antoni Sureda, Miquel Martorell, Xavier Capó, Margalida Monserrat-Mesquida, Maria Magdalena Quetglas-Llabrés, Mahsa Rasekhian, Seyed M. Nabavi, Silvia Tejada. Antitumor Effects of Triterpenes in Hepatocellular CarcinomaCurrent Medicinal Chemistry 2021; 28(13): 2465 doi: 10.2174/0929867327666200602132000
43
Wenzhen Li, Yifan Wang, Xinbo Zhou, Xiaohong Pan, Junhong Lü, Hongliu Sun, Zeping Xie, Shayan Chen, Xue Gao. The anti-tumor efficacy of 20(S)-protopanaxadiol, an active metabolite of ginseng, according to fasting on hepatocellular carcinomaJournal of Ginseng Research 2022; 46(1): 167 doi: 10.1016/j.jgr.2021.06.002
44
Zhijia Sun, Chunyuan Xue, Jiangbo Li, Hui Zhao, Yimeng Du, Nan Du. LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1Bioengineered 2022; 13(3): 7635 doi: 10.1080/21655979.2022.2050073
45
Fu He, Kangjian Song, Ge Guan, Junyu Huo, Yang Xin, Tianxiang Li, Chao Liu, Qingwei Zhu, Ning Fan, Yuan Guo, Liqun Wu. The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular CarcinomaPharmacogenomics and Personalized Medicine 2021; : 723 doi: 10.2147/PGPM.S313848
46
Tatjana Zekić, Mirjana Stanić Benić. Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based reviewRheumatology International 2022; 43(3): 559 doi: 10.1007/s00296-022-05247-5
47
Marhaba Nurmamat, Haili Yan, Ru Wang, Huixin Zhao, Yanhong Li, Xiaojing Wang, Kaidirye Nurmaimaiti, Tamasha Kurmanjiang, Difang Luo, Jumagul Baodi, Guancheng Xu, Jinyu Li. Novel Copper(II) Complex with a 4-Acylpyrazolone Derivative and Coligand Induce Apoptosis in Liver Cancer CellsACS Medicinal Chemistry Letters 2021; 12(3): 467 doi: 10.1021/acsmedchemlett.0c00680
48
Rui Zhang, Wei-Jia Mo, Lan-Shan Huang, Ji-Tian Chen, Wei-Zi Wu, Wei-Ying He, Zhen-Bo Feng. Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular CarcinomaBioengineered 2021; 12(1): 855 doi: 10.1080/21655979.2021.1890399
49
Yan-Fei Li, Fang-Yuan Zheng, Xin-Yu Miao, Hai-Long Liu, Yao-Yao Zhang, Nai-Xia Chao, Fa-Rong Mo. Cell division cyclin 25C knockdown inhibits hepatocellular carcinoma development by inducing endoplasmic reticulum stressWorld Journal of Gastroenterology 2024; 30(19): 2564-2574 doi: 10.3748/wjg.v30.i19.2564
50
Linjun Liang, Xiaoyan Wang, Shuying Huang, Yanwei Chen, Peng Zhang, Liang Li, Yong Cui. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinomaFrontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1046771
51
Xiaoqin Lv, Xia Xiang, Yue Wu, Yang Liu, Ruqing Xu, Qin Xiang, Guoqi Lai. GATA binding protein 4 promotes the expression and transcription of hepatitis B virus by facilitating hepatocyte nuclear factor 4 alpha in vitroVirology Journal 2021; 18(1) doi: 10.1186/s12985-021-01668-z
52
Yue Hu, Min Zhou, Jing Tang, Shuang Li, Hongli Liu, Jianli Hu, Hong Ma, Junli Liu, Tingting Qin, Xiongjie Yu, Yongshun Chen, Jin Peng, Yanmei Zou, Tao Zhang, Jun Xue. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor ThrombusClinical Cancer Research 2023; 29(20): 4088 doi: 10.1158/1078-0432.CCR-22-2592
53
Jose J.G. Marin, Rocio I.R. Macias, Maria J. Monte, Marta R. Romero, Maitane Asensio, Anabel Sanchez-Martin, Candela Cives-Losada, Alvaro G. Temprano, Ricardo Espinosa-Escudero, Maria Reviejo, Laura H. Bohorquez, Oscar Briz. Molecular Bases of Drug Resistance in Hepatocellular CarcinomaCancers 2020; 12(6): 1663 doi: 10.3390/cancers12061663
54
Raffaele Borriello, Lucia Cerrito, Antonio Gasbarrini, Francesca Romana Ponziani. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overviewExpert Opinion on Drug Metabolism & Toxicology 2023; 19(11): 785 doi: 10.1080/17425255.2023.2272598
55
Xuan-Yu Gu, Jin-Long Huo, Zhi-Yong Yu, Ji-Chang Jiang, Ya-Xuan Xu, Li-Jin Zhao. Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effectsOncologie 2024; 26(1): 9 doi: 10.1515/oncologie-2023-0412
56
Federico Piñero, Marcos Thompson, Juan Ignacio Marín, Marcelo Silva. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?World Journal of Transplantation 2020; 10(11): 297-306 doi: 10.5500/wjt.v10.i11.297
57
Julia C. F. Quintanilha, Susan Geyer, Amy S. Etheridge, Alessandro Racioppi, Kelli Hammond, Daniel J. Crona, Carol E. Peña, Sawyer B. Jacobson, Federica Marmorino, Daniele Rossini, Chiara Cremolini, Hanna K. Sanoff, Ghassan K. Abou-Alfa, Federico Innocenti. KDR genetic predictor of toxicities induced by sorafenib and regorafenibThe Pharmacogenomics Journal 2022; 22(5-6): 251 doi: 10.1038/s41397-022-00279-3
58
Michele Dal Bo, Elena De Mattia, Lorena Baboci, Silvia Mezzalira, Erika Cecchin, Yehuda G. Assaraf, Giuseppe Toffoli. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinomaDrug Resistance Updates 2020; 51: 100702 doi: 10.1016/j.drup.2020.100702
59
Ying Jia, Yufei Xing, Meitian Yang, Muhammad Wasim Khan. Efficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGTJournal of Oncology 2021; 2021: 1 doi: 10.1155/2021/9120265
60
Qinglong Yang, Gang Wu. CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expressionGastroenterología y Hepatología 2022; 45(10): 742 doi: 10.1016/j.gastrohep.2021.11.007
61
John R. Bergquist, Amy Y. Li, Christopher S. Javadi, Byrne Lee, Jeffrey A. Norton, George A. Poultsides, Monica M. Dua, Brendan C. Visser. Regional lymph node sampling in hepatoma resection: insight into prognosisHPB 2021; 23(9): 1360 doi: 10.1016/j.hpb.2021.01.006
62
Ewa Wolinska, Maciej Skrzypczak. Epigenetic Changes Affecting the Development of Hepatocellular CarcinomaCancers 2021; 13(16): 4237 doi: 10.3390/cancers13164237
63
Roland Sonntag, Christian Penners, Marlene Kohlhepp, Ute Haas, Daniela Lambertz, Andreas Kroh, Thorsten Cramer, Fabio Ticconi, Ivan G. Costa, Frank Tacke, Nikolaus Gassler, Christian Trautwein, Christian Liedtke. Cyclin E1 in Murine and Human Liver Cancer: A Promising Target for Therapeutic Intervention during Tumour ProgressionCancers 2021; 13(22): 5680 doi: 10.3390/cancers13225680
64
Xinyao Hu, Hua Zhu, Yang Shen, Xiaoyu Zhang, Xiaoqin He, Ximing Xu. The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular CarcinomaFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.696705
65
Renske Altena, Svetlana Bajalica-Lagercrantz, Andri Papakonstantinou. Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer TherapiesCancers 2022; 14(19): 4665 doi: 10.3390/cancers14194665